Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board
April 14, 2022 07:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company’s Scientific Advisory Board. Dr. Narendran is a...
Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting
April 11, 2022 07:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
March 24, 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has successfully developed and manufactured a second halogenated xanthene (HX), adding to...
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
March 16, 2022 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium)...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at American Association for Cancer Research (AACR) Annual Meeting 2022
February 08, 2022 05:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
February 01, 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium),...
Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
January 27, 2022 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene...
Provectus Biopharmaceuticals Announces Publication of Pharmaceutical-Grade Rose Bengal’s Activity Against Gram-Positive Bacteria
January 10, 2022 06:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on a formulation of the Company’s pharmaceutical-grade rose bengal against...
Provectus Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Single-Agent PV-10® in Stage III Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
November 01, 2021 08:00 ET
|
Provectus Biopharmaceuticals Inc.
184 patients: 44.9 months median overall survival774 PV-10-injected lesions (121 patients): 56% complete response KNOXVILLE, TN, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today...
Provectus Biopharmaceuticals Announces Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Treatment of Checkpoint-Refractory Advanced Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
October 28, 2021 06:00 ET
|
Provectus Biopharmaceuticals Inc.
34.1 months median overall survival, 4.9 months median progression-free survivalBest overall response (RECIST 1.1): 5% CR, 26% ORR, 53% DCR (19 patients) KNOXVILLE, TN, Oct. 28, 2021 (GLOBE...